Home Business Pharmaceutical sector fails to spring higher amid lackluster April performance (NYSE: PFE)

Pharmaceutical sector fails to spring higher amid lackluster April performance (NYSE: PFE)


Financial stock market graph.  Selective focus.

Diego Thomazini / iStock via Getty Images

With April 2022 trading in the books, the US large pharmaceutical sector had a fairly mediocre month, though it still performed better than the S&P 500 Index.

The iShares US Pharmaceuticals ETF (IHE), which tracks the Dow Jones US Select Pharmaceuticals Index, finished the month down 2.3%. By comparison, the S&P 500 lost 5.6% in April.

The two largest holdings in the fund are Johnson & Johnson (NYSE: JNJ) and Pfizer (NYSE: PFE), which account for, respectively, 22.5% and 20.8% of total holdings. J&J (JNJ) gained 3% in the month while Pfizer was down 2%.

The best performing large US pharma in April was Merck (NYSE: MRK) with a ~ 6.1% return. The company surged late in the month following its strong Q1 2022 results which were driven by a 50% year-over-year increase in global revenues helped by sales of its COVID-19 pill molnupiravir.

The pharma with the second highest return in the month was Bristol-Myers Squibb (BMY) which gained 4.6%. Bristol ended the month on a down note following its Q1 results.

The worst performing large US pharma was AbbVie (NYSE: ABBV), which was hit on April 29 by a quarterly revenue miss and a lowering of full-year EPS.

Read why Seeking Alpha contributor Edmund Ingham argues that Merck (MRK) is the best big pharma company to own today.

Previous articleRari Fuze hacker offered $ 10M bounty by Fei Protocol to return $ 80M loot By Cointelegraph
Next articleAt the Berkshire Hathaway meeting, Warren Buffett aims to assure shareholders


Please enter your comment!
Please enter your name here